Clinical trial
TEACO: Taxotere, Eloxatin, Avastin in Cancer of the Ovary
NCT00296816 · Sanofi, Industry · Completed
Key facts
| NCT number | NCT00296816 |
|---|---|
| Title | TEACO: Taxotere, Eloxatin, Avastin in Cancer of the Ovary |
| Official title | A Pilot Phase II Study Evaluating the Combination of Oxaliplatin and Docetaxel With Bevacizumab as First Line Therapy in Patients With FIGO Stage IB-IV Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Carcinoma |
| Acronym | TEACO |
| Lead sponsor | Sanofi, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Ovarian Cancer |
| Intervention type | Drug |
| Interventions | Bevacizumab (Avastin®), Docetaxel (Taxotere®), Oxaliplatin (Eloxatin®) |
| Enrollment | 132 |
| Start date | Mar 1, 2006 |
| Primary completion | Aug 1, 2011 |
| Completion | Aug 1, 2011 |
| First posted | Feb 27, 2006 |
| Last update posted | Aug 23, 2012 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: